Literature DB >> 11399020

Flucytosine primary resistance in Candida species and Cryptococcus neoformans.

M Cuenca-Estrella1, T M Díaz-Guerra, E Mellado, J L Rodríguez-Tudela.   

Abstract

The in vitro activity of flucytosine (5FC) against 1,140 clinical isolates of Candida spp. and Cryptococcus neoformans was evaluated and compared with the activity of amphotericin B, fluconazole and itraconazole. Overall, 87.72% (1,000/1,140) of yeasts were susceptible to 5FC. This agent showed less potent in vitro activity against Candida glabrata, Candida krusei, Candida guilliermondii and Cryptococcus neoformans (MIC90s, 8-16 microg/ml) and intermediate activity or resistance to 6.5% of Candida albicans, 5.1% of Candida tropicalis and 0.8% of Candida parapsilosis strains. Amphotericin B showed potent activity against isolates with an MIC of 5FC > or = 8 microg/ml. A total of 112 of 140 strains that were SFC-intermediate or -resistant showed decreased susceptibility to azoles (P < 0.01).

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11399020     DOI： 10.1007/pl00011265

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  15 in total

1.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.

Authors:  M A Pfaller; A Espinel-Ingroff; E Canton; M Castanheira; M Cuenca-Estrella; D J Diekema; A Fothergill; J Fuller; M Ghannoum; R N Jones; S R Lockhart; E Martin-Mazuelos; M S C Melhem; L Ostrosky-Zeichner; P Pappas; T Pelaez; J Peman; J Rex; M W Szeszs
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

6.  Candida dubliniensis at a university hospital in Saudi Arabia.

Authors:  R Fotedar; S S A Al-Hedaithy
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

7.  Chitinases are essential for sexual development but not vegetative growth in Cryptococcus neoformans.

Authors:  Lorina G Baker; Charles A Specht; Jennifer K Lodge
Journal:  Eukaryot Cell       Date:  2009-09-04

8.  Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans.

Authors:  Andrew R Dodgson; Kirsty J Dodgson; Claude Pujol; Michael A Pfaller; David R Soll
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

10.  Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter.

Authors:  Thierry Noël; Fabienne François; Patrick Paumard; Christiane Chastin; Daniel Brèthes; Jean Villard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.